Low Alcohol Use Disorder Treatment Rates Seen in Cancer Survivors
By Elana Gotkine HealthDay Reporter
THURSDAY, May 29, 2025 -- For U.S. adult cancer survivors with a new alcohol use disorder (AUD) diagnosis, the one-year cumulative incidence of AUD treatment initiation was 14.3 percent, according to a research letter published online May 27 in the Annals of Internal Medicine.
Anton L.V. Avanceña, Ph.D., from The University of Texas at Austin, and colleagues estimated the cumulative incidence of U.S. Food and Drug Administration-approved medications for AUDs (MAUDs) and initiation of psychosocial therapy among cancer survivors in a retrospective cohort study using Merative MarketScan claims data from January 2011 to December 2021. The sample was limited to cancer survivors with a new AUD diagnosis.
Data were included for 71,875 cancer survivors who received an AUD diagnosis. The researchers found that the one-year cumulative incidence of AUD treatment initiation was 14.3 percent. The one-year cumulative incidence of psychosocial therapy initiation was 12.6 percent, while the cumulative incidence of U.S. Food and Drug Administration-approved MAUD initiation was 2.8 percent. Within a year after AUD diagnosis, only 0.95 percent of cancer survivors received both FDA-approved MAUD and psychosocial therapy. Compared with male cancer survivors, female cancer survivors had a higher one-year cumulative incidence of AUD treatment initiation (18.2 versus 12.2 percent). Incidence was also higher for cancer survivors aged younger than 65 years versus those aged 65 years or older (17.2 versus 8.3 percent).
"Low rates of AUD treatment may be influenced by system-level factors like low provider knowledge about MAUDs as well as patient-level factors, including beliefs that AUD will resolve on its own and stigma associated with AUD," the authors write.
Abstract/Full Text (subscription or payment may be required
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
AAP Updates Screening Guidance for Child Mental Health, Behavioral Problems
MONDAY, Aug. 25, 2025 -- In a clinical report issued by the American Academy of Pediatrics and published online Aug. 25 in Pediatrics, updated recommendations are presented for...
Discordance Seen Between Care Goals, Treatment Intent in Advanced Cancer
MONDAY, Aug. 25, 2025 -- More patients with advanced cancer report that their treatment discordantly focuses on longevity over comfort than patients with other illnesses...
Apitegromab Improves Motor Function in Spinal Muscular Atrophy
MONDAY, Aug. 25, 2025 -- For patients with nonambulatory type 2 or type 3 spinal muscular atrophy, apitegromab, a monoclonal antibody that inhibits myostatin activation, improves...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.